AnGes, Inc. Logo

AnGes, Inc.

Biopharmaceutical firm developing gene-based and nucleotide-based medicines.

4563 | T

Overview

Corporate Details

ISIN(s):
JP3127700007
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7番15号

Description

AnGes, Inc. is a biopharmaceutical company specializing in the research and development of gene-based and nucleotide-based medicines. The company's core focus is its Hepatocyte Growth Factor (HGF) gene therapy product, designed to treat ischemic diseases by regenerating blood vessels. This product was the first gene therapy medicine to receive marketing approval in Japan. AnGes leverages its expertise in plasmid DNA technology across its development pipeline, which also includes an NFkB decoy oligonucleotide and DNA vaccines. The company is dedicated to developing novel treatments for various conditions, including rare diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-03-30 02:36
有価証券報告書-第21期(平成31年1月1日-令和1年12月31日)
Japanese 1.4 MB
2020-02-17 07:04
訂正有価証券報告書-第20期(平成30年1月1日-平成30年12月31日)
Japanese 643.4 KB
2020-02-17 07:00
訂正四半期報告書-第20期第3四半期(2018/07/01-2018/09/30)
Japanese 155.8 KB
2019-11-08 01:52
四半期報告書-第21期第3四半期(2019/07/01-2019/09/30)
Japanese 183.5 KB
2019-08-09 02:15
四半期報告書-第21期第2四半期(2019/04/01-2019/06/30)
Japanese 280.0 KB
2019-05-13 02:24
四半期報告書-第21期第1四半期(2019/01/01-2019/03/31)
Japanese 207.9 KB
2019-03-29 02:07
有価証券報告書-第20期(平成30年1月1日-平成30年12月31日)
Japanese 1.1 MB
2018-11-09 01:14
四半期報告書-第20期第3四半期(2018/07/01-2018/09/30)
Japanese 206.4 KB
2018-08-10 02:11
四半期報告書-第20期第2四半期(2018/04/01-2018/06/30)
Japanese 240.5 KB
2018-05-11 02:08
四半期報告書-第20期第1四半期(2018/01/01-2018/03/31)
Japanese 176.2 KB
2018-03-30 02:39
有価証券報告書-第19期(平成29年1月1日-平成29年12月31日)
Japanese 1.1 MB
2017-11-10 01:23
四半期報告書-第19期第3四半期(2017/07/01-2017/09/30)
Japanese 249.3 KB
2017-08-14 02:51
四半期報告書-第19期第2四半期(2017/04/01-2017/06/30)
Japanese 238.3 KB
2017-05-11 02:15
四半期報告書-第19期第1四半期(2017/01/01-2017/03/31)
Japanese 220.6 KB
2017-03-31 02:53
有価証券報告書-第18期(2016/01/01-2016/12/31)
Japanese 1.1 MB

Automate Your Workflow. Get a real-time feed of all AnGes, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AnGes, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AnGes, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.